TransCode and MD Anderson partner to advance RNA-targeted cancer therapies

TransCode and MD Anderson collaborate on preclinical studies to advance the former’s RNA-targeted oncology therapeutic and diagnostic candidates. Credit: The University of Texas MD Anderson Cancer Center.